Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJan 11, 2026
DataAggregated Company Financials
Companies63
  • 7D4.7%
  • 3M14.3%
  • 1Y6.2%
  • YTD4.7%

The Life Sciences industry is up 4.7% in the last week, with Thermo Fisher Scientific up 4.4%. In the last 12 months, the industry was up 6.2%. Looking forward, earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 11 Jan 2026US$699.1bUS$145.8bUS$12.4b37.1x56.5x4.8x
Tue, 09 Dec 2025US$659.4bUS$145.8bUS$12.5b35.7x52.9x4.5x
Thu, 06 Nov 2025US$642.0bUS$145.5bUS$12.1b34.1x53.2x4.4x
Sat, 04 Oct 2025US$620.2bUS$144.3bUS$14.6b31.2x42.6x4.3x
Mon, 01 Sep 2025US$585.1bUS$144.3bUS$14.6b29.2x40.2x4.1x
Wed, 30 Jul 2025US$583.6bUS$143.7bUS$8.8b38.6x66.2x4.1x
Fri, 27 Jun 2025US$534.3bUS$142.9bUS$9.2b36x58.3x3.7x
Sun, 25 May 2025US$494.4bUS$142.8bUS$9.1b31.6x54.4x3.5x
Tue, 22 Apr 2025US$503.8bUS$142.6bUS$10.0b33.9x50.6x3.5x
Thu, 20 Mar 2025US$599.3bUS$143.0bUS$9.9b38.5x60.5x4.2x
Sat, 15 Feb 2025US$618.3bUS$143.3bUS$10.0b34.4x61.8x4.3x
Mon, 13 Jan 2025US$671.3bUS$142.4bUS$10.2b43.2x65.8x4.7x
Wed, 11 Dec 2024US$678.3bUS$142.4bUS$10.2b44.7x66.3x4.8x
Fri, 08 Nov 2024US$702.9bUS$142.4bUS$10.4b43.2x67.8x4.9x
Sun, 06 Oct 2024US$733.8bUS$141.8bUS$8.5b37.6x86.4x5.2x
Tue, 03 Sep 2024US$749.6bUS$141.8bUS$8.5b37.8x88.2x5.3x
Thu, 01 Aug 2024US$749.1bUS$140.9bUS$12.5b37.9x59.7x5.3x
Sat, 29 Jun 2024US$682.1bUS$141.3bUS$12.2b37.9x56x4.8x
Mon, 27 May 2024US$726.8bUS$141.5bUS$12.4b38.7x58.5x5.1x
Wed, 24 Apr 2024US$721.5bUS$142.0bUS$12.7b41.3x56.9x5.1x
Fri, 22 Mar 2024US$744.1bUS$142.1bUS$12.8b45x58x5.2x
Sun, 18 Feb 2024US$720.7bUS$142.2bUS$12.5b43.3x57.5x5.1x
Tue, 16 Jan 2024US$684.9bUS$153.9bUS$14.2b35.4x48.3x4.5x
Thu, 14 Dec 2023US$653.3bUS$153.7bUS$14.2b36.9x45.9x4.2x
Sat, 11 Nov 2023US$582.1bUS$153.8bUS$13.9b30.9x41.7x3.8x
Mon, 09 Oct 2023US$644.8bUS$154.6bUS$11.2b33.1x57.5x4.2x
Wed, 06 Sep 2023US$717.8bUS$154.6bUS$11.2b32.2x64.1x4.6x
Fri, 04 Aug 2023US$724.9bUS$154.7bUS$11.5b30.6x62.9x4.7x
Sun, 02 Jul 2023US$697.8bUS$152.4bUS$12.5b29.5x55.8x4.6x
Tue, 30 May 2023US$677.3bUS$152.2bUS$12.5b27.7x54.2x4.5x
Thu, 27 Apr 2023US$685.2bUS$154.2bUS$10.6b28.3x64.9x4.4x
Sat, 25 Mar 2023US$705.3bUS$154.5bUS$10.8b26.1x65.2x4.6x
Mon, 20 Feb 2023US$744.5bUS$154.2bUS$10.9b31.7x68x4.8x
Wed, 18 Jan 2023US$765.0bUS$155.3bUS$8.5b30.7x89.7x4.9x
Price to Earnings Ratio

89.7x


Total Market Cap: US$765.0bTotal Earnings: US$8.5bTotal Revenue: US$155.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 59.8x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 56.5x which is lower than its 3-year average PE of 59.8x.
  • The industry is trading close to its 3-year average PS ratio of 4.5x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 13% per year over the last three years.
  • Meanwhile revenues for these companies have declined 2.1% per year.
  • This means that less sales are being generated overall, but since cost of doing business is lower, profits have been increasing.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.88%
Healthcare2.10%
Life Sciences4.68%
Clinical Research and Equipment4.68%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$618.864.4%
+US$9.9b		14.1%PE35.4x
DHR DanaherUS$238.373.5%
+US$5.6b		1.4%PE48.1x
A Agilent TechnologiesUS$148.527.7%
+US$3.0b		8.0%PE32.3x
IQV IQVIA HoldingsUS$242.417.6%
+US$2.9b		19.3%PE32.2x
MTD Mettler-Toledo InternationalUS$1.49k5.2%
+US$1.5b		22.6%PE36.3x

Latest News

BRKR
US$54.46
Bruker
7D
13.2%
1Y
-10.4%
MTD
US$1,485.12
Mettler-Toledo International
7D
5.2%
1Y
22.6%
ILMN
US$141.07
Illumina
7D
5.0%
1Y
3.2%
IQV
US$242.41
IQVIA Holdings
7D
7.6%
1Y
19.3%

IQVIA Holdings Inc.'s (NYSE:IQV) P/E Still Appears To Be Reasonable

Jan 09
IQVIA Holdings Inc.'s (NYSE:IQV) P/E Still Appears To Be Reasonable
ICLR
US$181.38
ICON
7D
-3.9%
1Y
-16.9%
LFCR
US$7.56
Lifecore Biomedical
7D
-2.3%
1Y
20.2%

LFCR: New Index Inclusion And CDMO Agreements Will Support Balanced Outlook

Analysts now place a neutral US$8.75 price target on Lifecore Biomedical, with the change supported by updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors reflect a slightly more cautious yet still constructive outlook on the shares.
TECH
US$65.70
Bio-Techne
7D
10.1%
1Y
-10.4%

TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook

Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).
WST
US$275.52
West Pharmaceutical Services
7D
-0.3%
1Y
-16.9%

WST: Normalizing Markets And 2026 Visibility Will Support Earnings Power

Narrative update The updated analyst price target for West Pharmaceutical Services reflects a largely steady fair value near US$346. Analysts point to recent target hikes, higher EPS estimates and a constructive view on growth drivers into 2026 as key supports for the current valuation framework.
TMO
US$618.86
Thermo Fisher Scientific
7D
4.4%
1Y
14.1%

TMO: Life Science Scale And 2026 Tools Demand Will Support Steady Performance

Analysts have nudged their fair value estimate for Thermo Fisher Scientific higher from about $626 to roughly $642, citing a series of recent price target increases that reflect updated models after Q3 results, expectations for healthier end markets and tools demand into 2026, and the company's scale in life science tools and lab supplies. Analyst Commentary Recent Street research on Thermo Fisher Scientific clusters around a consistent, more constructive view on the company, with several firms lifting their fair value estimates following the latest Q3 update.
ADPT
US$15.76
Adaptive Biotechnologies
7D
-0.9%
1Y
142.5%
DHR
US$238.37
Danaher
7D
3.5%
1Y
1.4%

DHR: Share Repurchases And Diagnostics Resilience Will Support Premium Multiple

Analysts have made a modest upward adjustment to their fair value estimate for Danaher to about US$259 from about US$258, reflecting slightly higher assumed profit margins and P/E, even as they highlight tempered expectations for 2025 and 2026 growth, ongoing uncertainty in China, and questions around how durable diagnostics demand will be. Analyst Commentary Analysts are split on Danaher, with some focusing on the valuation premium and others on the company’s ability to eventually reconnect with its historical growth profile.
A
US$148.52
Agilent Technologies
7D
7.7%
1Y
8.0%
HBIO
US$0.63
Harvard Bioscience
7D
-3.3%
1Y
-66.8%
ATLN
US$1.93
Atlantic International
7D
-5.4%
1Y
-64.7%

Not Many Are Piling Into Atlantic International Corp. (NASDAQ:ATLN) Stock Yet As It Plummets 33%

Dec 06
Not Many Are Piling Into Atlantic International Corp. (NASDAQ:ATLN) Stock Yet As It Plummets 33%
RPID
US$3.13
Rapid Micro Biosystems
7D
-0.3%
1Y
203.9%

Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 37% Jump Shows Its Popularity With Investors

Nov 14
Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 37% Jump Shows Its Popularity With Investors
MXCT
US$1.43
MaxCyte
7D
-7.7%
1Y
-67.5%